News Quantified

CBIO – crescent biopharma, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.

Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.

Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at Wall Street

Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at Guggenheim to a "strong-buy" rating.

Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.

Top News Gainers

12/19 Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration 65.8%

2/12 Catalyst Biosciences Announces Proposed Public Offering of Common Stock 30.0%

10/2 Form 4 CATALYST BIOSCIENCES, For: Oct 01 Filed by: LAWLOR AUGUSTINE 24.6%

4/3 Form 4 CATALYST BIOSCIENCES, For: Apr 01 Filed by: Ling Geoffrey M.D. 15.2%

2/7 Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress 13.6%

10/2 22NW: Catalyst Biosciences Needs Change Now 9.7%

3/12 Form SC 13G CATALYST BIOSCIENCES Filed by: Stonepine Capital Management, LLC 7.3%

2/27 Catalyst Biosciences Inc (NASDAQ: CBIO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock. 6.9%

8/1 Q2/2019 6/30/2019 EPS -1.150 ZacksConsensus -1.200 ActVsEst 0.050 - Beat 6.7%

4/28 Catalyst Biosciences Inc (NASDAQ: CBIO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.8%

Top News Decliners

6/17 Form 4 CATALYST BIOSCIENCES, For: Jun 13 Filed by: DESOUZA ERROL B -16.0%

3/13 Form 4 CATALYST BIOSCIENCES, For: Mar 13 Filed by: Richard John P -10.4%

2/24 Catalyst Biosciences to Present at the Cowen Healthcare Conference -9.0%

3/17 Form 4 CATALYST BIOSCIENCES, For: Mar 16 Filed by: Levy Howard -8.6%

8/26 Catalyst Biosciences Inc (NASDAQ: CBIO) was given a new $25.00 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.2%

8/1 Form 8-K CATALYST BIOSCIENCES, For: Aug 01 -7.1%

11/12 Catalyst Biosciences to Present at the Stifel Healthcare Conference -6.4%

12/9 Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference -6.2%

9/26 Catalyst Biosciences to Present at the Cantor Global Healthcare Conference -4.8%

2/12 Form 4 CATALYST BIOSCIENCES, For: Feb 10 Filed by: Levy Howard -4.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day